Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Price:
0.87 USD
-0.23%
Market Closed
Updated:
May 18, 2024
Balance Sheet
Balance Sheet Decomposition
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
| Current Assets | 20.9m |
| Cash & Short-Term Investments | 19.8m |
| Other Current Assets | 1.1m |
| Non-Current Assets | 1.3m |
| PP&E | 695k |
| Other Non-Current Assets | 559k |
| Current Liabilities | 4.8m |
| Accounts Payable | 516k |
| Accrued Liabilities | 4.3m |
| Non-Current Liabilities | 316k |
| Other Non-Current Liabilities | 316k |
Balance Sheet
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
Currency: USD
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|
| Assets | |||||
| Cash & Cash Equivalents |
12
|
15
|
14
|
9
|
|
| Cash Equivalents |
12
|
15
|
14
|
9
|
|
| Short-Term Investments |
0
|
46
|
26
|
10
|
|
| Other Current Assets |
0
|
2
|
2
|
1
|
|
| Total Current Assets |
12
|
63
|
42
|
21
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
1
|
|
| Total Assets |
12
N/A
|
64
+416%
|
43
-33%
|
22
-49%
|
|
| Liabilities | |||||
| Accounts Payable |
0
|
1
|
2
|
1
|
|
| Accrued Liabilities |
1
|
1
|
5
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
3
|
7
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
|
| Total Liabilities |
2
N/A
|
3
+73%
|
7
+137%
|
5
-25%
|
|
| Equity | |||||
| Common Stock |
0
|
0
|
0
|
0
|
|
| Retained Earnings |
24
|
36
|
64
|
89
|
|
| Additional Paid In Capital |
35
|
98
|
101
|
106
|
|
| Treasury Stock |
0
|
0
|
1
|
0
|
|
| Total Equity |
11
N/A
|
61
+469%
|
36
-41%
|
17
-53%
|
|
| Total Liabilities & Equity |
12
N/A
|
64
+416%
|
43
-33%
|
22
-49%
|
|
| Shares Outstanding | |||||
| Common Shares Outstanding |
1
|
14
|
15
|
14
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
